We investigated the pharmacokinetics (PK) of aripiprazole, a newly developed antipsychotic, and its active metabolite in healthy Japanese, and the in‰uence of CYP2D6 polymorphism on the PK of aripiprazole. Following a single oral 6 mg dose, the mean Cmax, tmax, and t1/2, z (terminal phase half life) of aripiprazole were 31.0 ng/mL, 3.6 hr, and 61.0 hr, respectively. The t1/2, z in CYP2D6 IM subjects (75.2 hr) was signiˆcantly (p＜0.01) longer than that in CYP2D6 EM subjects (45.8 hr), and the systemic clearance of IM subjects was approximately 60z that of EM subjects. The PK in one subject with the CYP2D6*41 homozygote was similar to that of IM subjects. In repeated oral administration, plasma concentrations of aripiprazole and active metabolite both reached a steady state by Day 14. The half-life of aripiprazole following repeated administration was similar to that following single administration, suggesting that pharmacokinetics was constant during 14-day administration. Our investigations revealed that there is no clear ethnic diŠerence between Japanese and Western subjects in terms of mean plasma PK, while the CYP2D6*10 allele distinctive to Asian populations in‰uences the PK of aripiprazole. Moreover, our observations suggest that the CYP2D6 * 41 allele signiˆcantly aŠects drug-metabolizing activity.
Introduction
Aripiprazole (ARI, Fig. 1 ) is a new antipsychotic 1) and has already been placed in the market in various countries including the US, the EU, and Japan. The in vitro studies have indicated that ARI is mainly metabolized by human cytochrome P450 isoforms CYP3A4 and CYP2D6. [2] [3] [4] The main metabolic pathway of ARI in humans is the dehydrogenation of ARI to OPC-14857 ( Fig. 1) , and the level of other plasma metabolites is extremely low in comparison to those of ARI and OPC-14857. OPC-14857 is slowly oxidized by CYP3A4. 4) In a previous study, we investigated the eŠect of concomitant administration of CYP3A4 inhibitor (itraconazole) on the pharmacokinetics (PK) of ARI in Japanese subjects with the genotypes that in‰uence CYP2D6 activity. The concomitant administration of itraconazole at the clinical dose of 100 mg reduced the systemic clearance (CL/F) of ARI by approximately 30 and 50z in CYP2D6 extensive metabolizers (EM) and intermediate metabolizers (IM), respectively. 5) Although a recent work has claimed that among genetic CYP3A4 polymorphisms aŠect catalytic activity, 6) it is generally considered that there is almost no genotype in‰uencing CYP3A4 metabolic activity. 7) However, there are polymorphisms aŠecting CYP2D6 metabolic activity and the existence of ethnic diŠerences in the genotypes and the frequency of allele mutation have been reported. [8] [9] [10] [11] It was thus considered that the PK of ARI might be aŠected by CYP2D6 genotype, and therefore CYP2D6 genotyping for subjects was carried out, and the PK of ARI was assessed according to each genotype.
The results of preclinical pharmacological studies indicated that the main metabolite of ARI, OPC-14857, has pharmacological activity equivalent to that of ARI, and CYP3A4 and CYP2D6 were involved in the production and elimination of OPC-14857.
2) Based on above background, we studied in more detail whether genetic polymorphism of CYP2D6 aŠects the PK of ARI and OPC-14875.
Methods
Subjects and ethical agreement: Prior to the screening examination, informed consent was obtained in writing from each subject to conˆrm their willingness to participate in the study. For the conduct of CYP2D6 genotyping and the handling of data obtained in the study, reference was made to``Fundamental Principles of Research on the Human Genome'' issued by the Bioethics Committee, Council of Science and Technology, on June 14, 2000, and to``Ethical Principles of Human Genome Research and Gene Analysis'' issued by the Ministry of Health, Labour, and Welfare etc. on March 29, 2001. In conducting this study, care was exercised to protect the privacy of the subjects, in accordance with the above-mentioned guidelines.
Drug administration and collection of blood: This clinical study was conducted at the Research Institute of Osaka Pharmacology Research Clinic (Osaka, Japan). In the case of single administration, twenty subjects chosen from the screening examination were orally administered one tablet containing 6 mg ARI with 150 mL water in a fasting state (after fasting for at least 10 hr). For the determination of plasma drug concentrations, 5 mL venous blood was collected using a heparinized plasma separation tube at 13 time points (before and 1, 2, 3, 4, 5, 6, 8, 12, 24, 48, 72 , and 168 hr after dosing). The collected blood was centrifuged at 1,800×g for 10 min to obtain the plasma, which was stored frozen at -20 9 C or below until assay. Subjects were required to stay in the above clinic from one day before administration until completion of the examination conducted at 72 hr after dosing. During that period, subjects were required not to take foods and beverages containing alcohol, caŠeine, or grapefruit, and all other foods and beverages not speciˆcally permitted. Smoking was prohibited from the time of admission to the clinic (one day before administration) until dinner on the day of administration. Subjects were required to keep sitting from immediately after administration until 4 hr after administration to minimize any possible in‰uence of posture change on absorption. In the study of multiple doses,ˆfteen subjects chosen from the screening examination were given once a day an ARI tablet (3 mg ARI) with 150 mL water 30 min after breakfast for 14 consecutive days.
During the drug administration period, blood samples were collected at 8 time points on Days 1, 7, and 14, and at 1 time point (just before dosing) on all other administration days. Blood samples were also collected at 8 time points following completion of study drug administration ( Days 15, 16, 17, 18, 19, 21, 23 , and 28).
CYP2D6 genotyping: For CYP2D6 genotyping, 10 mL of venous blood was collected from each subject using a heparinized blood collection tube prior to single administration and prior to the start of repeated administration, and polymorphisms in the CYP2D6 gene were investigated using the PCR-RELP and long-PCR methods. In this examination, the CYP2D6 alleles, including CYP2D6*2, CYP2D6*4, CYP2D6*5, CYP2D6*10, CYP2D6*14, and CYP2D6*18 were investigated based on the estimated percentage 10, 11) of each CYP2D6 allele in the Japanese population, and all alleles other than those were regarded as CYP2D6 * 1. After performing the CYP2D6 genotyping in this clinical study, CYP2D6*41 (-1584C, R296C, S486T; reduced activity) was found to coexist with CYP2D6*2. [12] [13] [14] Subjects initially judged as CYP2D6*2 zygote were grouped together as extra classiˆcation named Type *2, since it was impossible to distinguish the CYP2D6 * 41 allele (with decreased activity) from the CYP2D6*2 EM allele. CYP2D6 zygotes were classiˆed into the following 4 categories according to the anticipated metabolic enzyme activity of that allele. EM: CYP2D6 genotype identiˆed as a homozygote of CYP2D6 * 1 or a zygote of CYP2D6 * 1 and some other alleles (*1/*1, *1/*2, *1/*5, *1/*10, etc.); IM: CYP2D6 genotype identiˆed as a zygote of CYP2D6*10 and some other alleles except CYP2D6 * 1 or CYP2D6 * 2 (*5/*10, *10/*10, etc.); Poor metabolizer (PM): CYP2D6 genotype identiˆed as a homozygote or heterozygote of a defective gene (*4/*4, *5/*5, *4/*5, etc.); Type *2: CYP2D6 genotype is identiˆed as a homozygote or heterozygote (other than * 1/ * 2) of the *2 allele (*2/*2, *2/*5, *2/*10, *2/*14, etc.).
In addition, for 2 subjects of the single-dose group whose genotype was judged to be a homozygote of the *2 allele (*2/*2) in the initial CYP2D6 genotyping, the genotype at the -1584 site was determined by direct sequencing.
14)
Determination of plasma drug concentrations: Plasma concentrations of ARI and OPC-14857, were determined by Sumika Chemical Analysis Service, Ltd., using liquid chromatography tandem mass spectrometry (LC-MS/MS).
15) The lower limit of quantitation (LLO-Q) for both analytes was 0.1 ng/mL. For the concentration range of 0.1 to 100 ng/mL, intra-assay precision was º5.1z CV for ARI and º15.9z CV (at LLOQ) for OPC-14857.
Pharmacokinetic analysis: Pharmacokinetic parameters (Cmax, AUC, tmax, t1/2, z and CL/F) of ARI and OPC-14857 were calculated by a non-compartmental method using the PK analysis softwares PSAG-CP (Version 4. 
Results
Phenotypes and physical characters of subjects: During the study, there were no withdrawals from among the 20 subjects who received single administration of ARI and the 15 subjects who received repeated administration. The physical characters and CYP2D6 genotypes of subjects are shown in Table 1 . Of the 20 subjects who received single administration, 9 were classiˆed as EM, 9 were classiˆed as IM, and 2 were classied as Type *2. Of the 15 subjects who received repeated administration, 11 were classiˆed as EM, 1 was classiˆed as IM, and 3 were classiˆed as Type *2.
Assessment of pharmacokinetics: Study with single administration: The time courses of the mean plasma concentrations of ARI and OPC-14857, following single oral administration of one tablet containing 6 mg ARI in 20 healthy adult male subjects in a fasting condition are shown in Fig. 2 . The PK parameters of ARI and OPC-14857 following single oral administration are shown in Table 2 . The mean plasma ARI concentration of 20 subjects who took 6 mg ARI reached a maximum at 3.6 hr after administration. Subsequent elimination of ARI from the plasma was biphasic and slow, with a t1/2, z of over 60 hr. The plasma concentration of OPC-14857 increased gradually and reached a maximum the level of which was almost 1/10 of that of parent drug at approximately 70 hr after administration. Elimination of OPC-14857 until 168 hr was slower than elimination of ARI. The changes in the plasma concentrations of ARI and OPC-14857 in subjects with diŠer-ent CYP2D6 genotypes who took an ARI tablet are shown in Fig. 3 . Based on this, parameters for the PK of ARI were calculated ( Table 3 ). In the comparison of the PK of ARI, the t1/2, z in IM subjects was signiˆcantly longer than that in EM subjects, while Cmax did not diŠer between EM and IM ( Table 3) . AUC and CL/F were also signiˆcantly diŠerent between EM and IM subjects ( Table 3) . The relationship between CL/F and CYP2D6 genotype is summarized in Fig. 4 . Time course of OPC-14857 plasma concentration tin IM subjects was lower than that in EM subjects, although marked individual diŠerences were observed. The time-dependent change in the concentration of ARI and OPC-14857 in the Type *2 genotype were midway between those in the IM and EM groups. In addition, the full-length sequence of the CYP2D6 gene was determined in 2 subjects belonging to the Type *2 group who were judged to be homozygotes of the CYP2D6 * 2 (*2/*2) in the initial genotyping. From comparison with the CYP2D6 sequence reported thus far, 12, 13) it became clear that the genotype of one subject was CYP2D6*41/*41 and that of the another was CYP2D6 * 2/ * 41.
The subject genotyped as CYP2D6*41/*41 showed a plasma concentration proˆle similar to that in the IM group (especially t1/2, z) and the subject genotyped as CYP2D6 * 2/ * 41 showed a time course close to that in the EM group.
Assessment of pharmacokinetics: study with repeated administration: Alteration in the plasma concentrations of ARI and OPC-14857 during repeated oral administration of 3 mg ARI for 14 days to 15 subjects is shown in Fig. 5 . The PK parameters of ARI and OPC-14857 are shown in Table 4) . Although the AUC 24hr values of OPC-14857 on Days 7 and 14 were also more abundant compared with that on Day 1, those values on Days 7 and 14 were below 27z of the values for ARI ( Table 4) . As described before (Table 1) , of 15 subjects who received repeated administration, 11 were classiˆed as EM, 1 was classiˆed as IM, and 3 were classiˆed as Type *2. The PK parameters of ARI and OPC-14857 on Days 1 and 14 (steady state) in subjects with diŠerent CYP2D6 genotypes are shown in Table 5 . Although the number of subjects classiˆed as IM was small (1 subject), both C max and AUC for ARI and OPC-14857 in the IM subject were higher than those in EM subjects. The AUC of ARI plus OPC-14857 was 20-30z greater than that of ARI alone in each of the CYP2D6 genotype groups. The combined AUC (ARI plus OPC-14857) in IM was approximately 3 times that in EM subjects, and that ratio was almost the same as that for the AUC of ARI only ( Table 5 ).
Discussion
The PK of ARI and its main metabolite, OPC-14857, following single administration and repeated administration was investigated. Since OPC-14857 has pharmacological activity on the central nervous system equivalent to that of ARI, 4) the PK of OPC-14857 was also assessed. Following single administration of ARI, the AUC168hr of OPC-14857 was approximately 20z of that of ARI, while the AUC∞ of OPC-14857 was increased to 50z of that in ARI, owing to the long t1/2,z of OPC-14857. The tmax of OPC-14857 after single administration varied between 24 and 168 hr among individual subjects and it is, therefore, considered that the number of sampling points in the elimination phase may have been insu‹cient for evaluation of t1/2, z and AUC∞. During repeated administration of ARI (3 mg/day) for 14 days, the mean C max of ARI on Days 7 and 14 was 3.2 and 3.7 times greater than that on Day 1, respectively. The t1/2, z of ARI after theˆnal administration (Day 14) was 64.6 hr, which was similar to the half-life (61.0 hr) following single administration at a dose of 6 mg in a fasting state. In addition, no change in CL/F was observed. It is, therefore, concluded that the PK of ARI did not change by repeated administration of ARI for 14 days; that is, neither metabolic enzyme induction nor saturation of CYP3A4 and CYP2D6 seems to occur following repeated administration.
The plasma PK of ARI in Japanese subjects in this study was similar to that in Western (American and European) subjects in a single dosing study 16) (t1/2, z: 84.7± 34.5 hr, CL/F/BW: 54.6±12.8 mL/h/kg at a dose of 15 mg) and repeated dosing study 17) (t 1/2, z : 56.1±8.8 hr, CL/F: 3.3±1.0 L/h, Robs: 4.0 at a dose of 5 mg), and thus there was no ethnic diŠerence seen between Japanese subjects and Western subjects in terms of mean plasma PK. The result of in vitro study indicated that ARI is metabolized by CYP3A4 and CYP2D6.
2) As for CYP2D6, a number of polymorphisms, the existence of ethnic diŠerences in the genotypes, and frequency of allele mutation have been reported. 8, 11) In Caucasians, the PM phenotype is caused mainly by the mutant alleles CYP2D6*3, *4, and *5. In contrast, CYP2D6*3, and *4 are rare in Asians. The Asianspeciˆc PM and IM alleles are assumed to be CYP2D6*14 and *10, respectively. In the present study, homozygous and heterozygous CYP2D6*1 were classied as extensive metabolizers. Homozygous CYP2D6*10, which is considered to have intermediate metabolic activity, and heterozygous CYP2D6 * 10 and CYP2D6*5, which are considered to have defective metabolic activity, were classiˆed as intermediate metabolizers. Homozygous CYP2D6*2 and heterozygous CYP2D6*2 with IM allele causing defective metabolic activity were classiˆed as Type *2, because of the possibility of including the CYP2D6 * 41 allele, which is thought to be inappropriate to classify into the EM group.
It has been reported that CYP2D6 IM genotypes account for approximately 20z of all Japanese. 8, 11) However, the ratio of IM subjects in our each studies was markedly diŠerent from above value. That is, 13z (3/24) in the previous study assessing the eŠect of itraconazole on the PK of ARI. 5) 45z (9/20) in the present study with single-dosing and 7z (1/15) in the present study with repeated-dosing. In the single-dosing study, because the number of IM subjects was almost equal to that of EM subjects, it was possible to evaluate the in‰uence of CYP2D6 polymorphism speciˆc to Asians (including Japanese) on the plasma PK of ARI in EM subjects and IM subjects. The data obtained in this single-dosing study indicated that EM and IM showed no diŠerence in the Cmax of ARI, and the AUC∞, which re‰ects the AUC 24hr on steady state in repeated administration, in IM was about 2-times greater than that in EM subjects. Therefore, diŠerences in the PK of ARI between EM and IM subjects were relatively small and not considered to pose a clinical problem. As the t1/2, z of ARI in 1 subject genotyped as homozygous CYP2D6*2 (Type *2) was as long as in IM subjects, it was suggested that this subject might be homozygous CYP2D6 * 41, an allele seen with extremely low frequency in Japanese. 14) From the comparison of the CYP2D6 sequence with literature data, 12, 13) it became evident that the genotype of this subject was indeed CYP2D6*41/*41. Taking also the previousˆndings concerning the in‰uence of CYP2D6*2 and *41 on sparteine metabolism into consideration, 18) our observation revealed that subjects with the CYP2D6*41 allele have decreased ARI-metabolizing activity.
An accurate comparison of the PK parameters of IM subjects in the single-dosing study with those of the repeated-dosing study was di‹cult due to the small number of IM subjects in the latter study (1 subject). However, in comparison of EM subjects between the single and repeated-dosing studies, both the t1/2, z and CL/F of ARI in the steady state (Day 14) were almost the same as those in the single-dosing study. AUC∞ in single dosing, which re‰ects the AUC on steady state in repeated dosing, in IM was about 2-times greater than that in EM subjects. Both AUC of ARI alone and the combined AUC (ARI plus OPC-14857) in IM subject at steady state in the repeated-dosing study was approximately 3 times that in EM subjects. Thus, it was presumed that the same pharmacological eŠect can be achieved in IM subjects as in EM subjects with 1/2-1/3 of the dose.
In conclusion, we described the plasma PK of ARI and its active metabolite in healthy Japanese subjects following single and repeated administration of the ARI, and conˆrmed that plasma PK is not aŠected by repeated administration and that there is no distinct ethnic diŠerence between Japanese and Western (US/EU) patients in terms of mean plasma PK. We also evaluated the in‰uence of CYP2D6 polymorphism (CYP2D6 * 10) speciˆc to Asians including Japanese on the plasma PK of ARI. Furthermore, despite a small sample size, we conˆrmed the relationship between the CYP2D6*41 genotype and the plasma PK of ARI. The data suggest that CYP2D6*41 allele is important as far as the in‰uence of CYP2D6 polymorphism on drug metabolism is concerned.
